|
1
|
Vestbo J, Hurd SS, Agustí AG, et al:
Global strategy for the diagnosis, management, and prevention of
chronic obstructive pulmonary disease: GOLD executive summary. Am J
Respir Crit Care Med. 187:347–365. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wulf-Johansson H, Thinggaard M, Tan Q, et
al: Circulating surfactant protein D is associated to mortality in
elderly women: a twin study. Immunobiology. 218:712–717. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sin DD, Man SF, Marciniuk DD, et al; ABC
(Advair, Biomarkers in COPD) Investigators. The effects of
fluticasone with or without salmeterol on systemic biomarkers of
inflammation in chronic obstructive pulmonary disease. Am J Respir
Crit Care Med. 177:1207–1214. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shakoori TA, Sin DD, Ghafoor F, Bashir S
and Bokhari SN: Serum surfactant protein D during acute
exacerbations of chronic obstructive pulmonary disease. Dis
Markers. 27:287–294. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ju CR, Liu W and Chen RC: Serum surfactant
protein D: biomarker of chronic obstructive pulmonary disease. Dis
Markers. 32:281–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sin DD, Leung R, Gan WQ and Man SP:
Circulating surfactant protein D as a potential lung-specific
biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med.
7:132007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
García-Laorden MI, Rodríguez de Castro F,
Solé-Violán J, et al: Influence of genetic variability at the
surfactant proteins A and D in community-acquired pneumonia: a
prospective, observational, genetic study. Crit Care.
15:R572011.PubMed/NCBI
|
|
8
|
Boonarkart CH, Suptawiwat O, Uiprasertkul
M, et al: A reduced expression of surfactant protein D in the lungs
of fatal influenza H1N1 cases in 2009. Acta Virol. 56:253–255.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Atochina-Vasserman EN, Winkler C, Abramova
H, et al: Segmental allergen challenge alters multimeric structure
and function of surfactant protein D in humans. Am J Respir Crit
Care Med. 183:856–864. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
King BA and Kingma PS: Surfactant protein
D deficiency increases lung injury during endotoxemia. Am J Respir
Cell Mol Biol. 44:709–715. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ware LB, Koyama T, Billheimer DD, et al;
NHLBI ARDS Clinical Trials Network. Prognostic and pathogenetic
value of combining clinical and biochemical indices in patients
with acute lung injury. Chest. 137:288–296. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sin DD, Man SF, McWilliams A and Lam S:
Surfactant protein D and bronchial dysplasia in smokers at high
risk of lung cancer. Chest. 134:582–588. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Madan T, Reid KB, Clark H, et al:
Susceptibility of mice genetically deficient in SP-A or SP-D gene
to invasive pulmonary aspergillosis. Mol Immunol. 47:1923–1930.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ichiyasu H, Ichikado K, Yamashita A, et
al: Pneumocyte biomarkers KL-6 and surfactant protein D reflect the
distinct findings of high-resolution computed tomography in
nonspecific interstitial pneumonia. Respiration. 83:190–197. 2012.
View Article : Google Scholar
|
|
15
|
Lomas DA, Silverman EK, Edwards LD, et al;
Evaluation of COPD Longitudinally to Identify Predictive Surrogate
Endpoints study investigators. Serum surfactant protein D is
steroid sensitive and associated with exacerbations of COPD. Eur
Respir J. 34:95–102. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vestbo J, Edwards LD, Scanlon PD, et al;
ECLIPSE Investigators. Changes in forced expiratory volume in 1
second over time in COPD. N Engl J Med. 365:1184–1192.
2011.PubMed/NCBI
|
|
17
|
Engström G, Lindberg C, Gerhardsson de
Verdier M, et al: Blood biomarkers and measures of pulmonary
function - a study from the Swedish twin registry. Respir Med.
106:1250–1257. 2012.PubMed/NCBI
|
|
18
|
Global Initiative for Chronic Obstructive
Lung Disease (GOLD). Global Strategy for the Diagnosis, Management,
and Prevention of Chronic Obstructive Pulmonary Disease. http://www.goldcopd.org/uri.
Accessed December 31, 2011
|
|
19
|
Miller MR, Hankinson J, Brusasco V, et al;
ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J.
26:319–338. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Beeh KM, Beier J, Kornmann O and Buhl R:
Sputum matrix metalloproteinase-9, tissue inhibitor of
metalloproteinase-1, and their molar ratio in patients with chronic
obstructive pulmonary disease, idiopathic pulmonary fibrosis and
healthy subjects. Respir Med. 97:634–639. 2003. View Article : Google Scholar
|
|
21
|
Sin DD and Vestbo J: Biomarkers in chronic
obstructive pulmonary disease. Proc Am Thorac Soc. 6:543–545. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Biomarkers Definitions Working Group.
Biomarkers and surrogate endpoints: preferred definitions and
conceptual framework. Clin Pharmacol Ther. 69:89–95. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Koutsokera A, Stolz D, Loukides S and
Kostikas K: Systemic biomarkers in exacerbations of COPD: the
evolving clinical challenge. Chest. 141:396–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
van Durme YM, Verhamme KM, Aarnoudse AJ,
et al: C-reactive protein levels, haplotypes, and the risk of
incident chronic obstructive pulmonary disease. Am J Respir Crit
Care Med. 179:375–382. 2009.PubMed/NCBI
|
|
25
|
Hartl D and Griese M: Surfactant protein D
in human lung diseases. Eur J Clin Invest. 36:423–435. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dickens JA, Miller BE, Edwards LD, et al;
Evaluation of COPD Longitudinally to Identify Surrogate Endpoints
(ECLIPSE) study investigators. COPD association and repeatability
of blood biomarkers in the ECLIPSE cohort. Respir Res. 12:1462011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hoegh SV, Sorensen GL, Tornoe I, et al:
Long-term stability and circadian variation in circulating levels
of surfactant protein D. Immunobiology. 215:314–320. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang IM, Stepaniants S, Boie Y, et al:
Gene expression profiling in patients with chronic obstructive
pulmonary disease and lung cancer. Am J Respir Crit Care Med.
177:402–411. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Foreman MG, Kong X, DeMeo DL, et al:
Polymorphisms in surfactant protein-D are associated with chronic
obstructive pulmonary disease. Am J Respir Cell Mol Biol.
44:316–322. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
The Chronic Obstructive Pulmonary Disease
group of Chinese Thoracic Society. The diagnosis and treatment
guideline of chronic obstructive pulmonary disease. Zhonghua Jie He
He Hu Xi Za Zhi. 30:8–17. 2007.(In Chinese).
|
|
31
|
Braido F, Bagnasco D, Scichilone N, et al:
Biomarkers in obstructive respiratory diseases: an update.
Panminerva Med. 54:119–127. 2012.PubMed/NCBI
|
|
32
|
Celli BR, Locantore N, Yates J, et al;
ECLIPSE Investigators. Inflammatory biomarkers improve clinical
prediction of mortality in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med. 185:1065–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
